Retinoschisis is a condition where the retina, the light-sensitive tissue lining the back of your eye, splits into two layers. This splitting creates fluid-filled pockets between the layers that can interfere with how the retina processes visual signals. There are two distinct forms: a genetic type that primarily affects boys and young men, and a degenerative type caused by aging that can affect anyone.
How the Retina Splits
The retina is made up of multiple thin layers of cells, each with a specific job in converting light into the electrical signals your brain interprets as vision. In retinoschisis, these layers separate from each other, most often at the level of the nerve fiber and ganglion cell layers. The split creates a gap that fills with fluid, forming cyst-like spaces within the retina itself. This is different from a retinal detachment, where the entire retina peels away from the tissue behind it.
In the center of the eye (the macula, responsible for sharp central vision), the splitting often occurs in deeper layers. On imaging scans, this appears as a characteristic pattern of tiny cysts scattered through the retinal layers. In the peripheral retina, the splitting tends to involve layers closer to the eye’s surface, sometimes forming larger, balloon-like elevations of retinal tissue.
X-Linked Juvenile Retinoschisis
The inherited form of retinoschisis is caused by mutations in a gene called RS1, located on the X chromosome. This gene provides instructions for making a protein called retinoschisin, which acts like a glue holding retinal cells together. It binds to both the cells that detect light and color (photoreceptors) and the cells that relay those signals deeper into the retina. When the gene is mutated, the protein doesn’t work properly, and the cellular adhesion that normally keeps retinal layers intact gradually fails. More than 220 different mutations in the RS1 gene have been identified.
Because the gene sits on the X chromosome, this form follows an X-linked inheritance pattern. Males have only one X chromosome, so a single copy of the mutated gene is enough to cause the condition. Females have two X chromosomes, so a working copy on their second X chromosome typically compensates. Women can be carriers and pass the gene to their sons, but they rarely develop symptoms themselves.
The condition is estimated to affect between 1 in 5,000 and 1 in 25,000 people. Most affected boys are identified during grade school, when routine vision screenings pick up reduced visual acuity. Some cases are caught as early as infancy. The hallmark finding is a spoke-wheel pattern of tiny cysts in the macula, visible during an eye exam. Peripheral retinal splitting occurs in many patients as well, though it may not cause noticeable symptoms on its own.
Degenerative Retinoschisis
The age-related form of retinoschisis has nothing to do with genetics. It develops as a consequence of normal aging and affects both men and women. The splitting typically occurs in the peripheral retina, away from the center of vision, which is why many people never realize they have it. It’s often discovered incidentally during a routine dilated eye exam.
Degenerative retinoschisis is considerably more common than the juvenile form and generally causes fewer problems. Most people with it retain good central vision throughout their lives. There is no medical treatment for it, and in the vast majority of cases, none is needed.
Symptoms and Vision Changes
In X-linked juvenile retinoschisis, the most common symptom is blurry central vision, since the macular cysts disrupt the area of the retina responsible for reading, recognizing faces, and seeing fine detail. Vision tends to be mildly to moderately reduced during childhood and may remain relatively stable for years or even decades. Many affected individuals maintain functional vision well into adulthood, though the degree varies widely from person to person.
When splitting is limited to the macula without further complications, most eyes retain relatively good vision. The concern is progression. If the condition advances to cause a retinal detachment, vision typically declines more significantly. Peripheral retinoschisis in either form can produce visual field defects (blind spots in your side vision), but because these develop slowly, they often go unnoticed.
How Retinoschisis Is Diagnosed
An eye doctor can often suspect retinoschisis during a dilated eye exam based on the appearance of the retina. Two additional tests help confirm the diagnosis and characterize its severity.
Optical coherence tomography (OCT) is the most informative tool. It produces cross-sectional images of the retina at near-microscopic resolution, making the splitting and cyst-like spaces directly visible. In the macula, OCT typically shows cystic changes in one or more of the retina’s inner layers. In the periphery, it reveals splitting and fluid-filled spaces that help doctors grade the severity from mild cystic changes to full bullous (bubble-like) splitting.
An electroretinogram (ERG) measures the electrical response of the retina to light flashes. In X-linked retinoschisis, the ERG shows a characteristic “negative” pattern where one specific component of the electrical signal (the b-wave) is reduced. This pattern is present in both early and advanced stages, making it useful for diagnosis even when the visible changes on exam are subtle. Family history of retinoschisis, retinal detachment, or unexplained vision loss in male relatives further supports the diagnosis.
Risk of Retinal Detachment
The most serious complication of retinoschisis is progression to a full retinal detachment. This happens when holes develop in both the inner and outer walls of the split retina, allowing fluid to pass through and separate the retina from the tissue underneath. Holes in the outer wall of the split occur in about 23% of cases of acquired peripheral retinoschisis, but the actual progression to a symptomatic retinal detachment is uncommon, estimated at between 0.05% and 2.2%.
One useful clinical distinction: retinoschisis alone typically does not produce hemorrhage or pigment changes in the retina. If an eye doctor sees those signs, it raises suspicion that the condition has progressed to a true retinal detachment. Overall, retinoschisis-related detachments account for roughly 3% of all retinal detachments.
Treatment Options
For degenerative retinoschisis, the standard approach is observation. Regular eye exams allow your doctor to monitor for any progression, but active treatment is rarely necessary.
For X-linked juvenile retinoschisis, management focuses on reducing the fluid-filled cysts in the macula. Carbonic anhydrase inhibitors, available as both eye drops and oral tablets, are the primary medical treatment. A study of 42 patients at Dutch and Belgian eye centers found that oral forms significantly reduced the thickness of the central macula (a measure of how much fluid is present), and topical drops also produced a measurable reduction. However, the improvement in actual visual sharpness was modest and not considered clinically significant. In other words, these medications can reduce the structural swelling but don’t reliably translate into noticeably better vision. They’re generally considered a short-term management tool rather than a cure.
Surgery becomes necessary when complications arise, particularly retinal detachment. The surgical options are the same as those used for other types of retinal detachment and aim to reattach the retina and seal any holes. For X-linked retinoschisis specifically, surgery may also be considered when vitreous hemorrhage (bleeding inside the eye) occurs or when the splitting progresses to threaten central vision.
Gene Therapy Research
Because X-linked juvenile retinoschisis is caused by a single gene, it’s a strong candidate for gene therapy. The idea is straightforward: deliver a working copy of the RS1 gene directly into the retina so the cells can produce functional retinoschisin protein. A clinical trial called LIGHTHOUSE is currently recruiting male patients aged 6 and older to test a gene therapy called ATSN-201, delivered as a one-time injection beneath the retina. The trial is in early phases, evaluating safety and tolerability over a five-year follow-up period. No results have been posted yet, but the approach represents the closest thing to a potential cure for the genetic form of the condition.